Literature DB >> 21486148

Use of oral dichloroacetate for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report.

Akbar Khan1.   

Abstract

Dichloroacetate sodium (DCA) is a nonproprietary drug currently used for treatment of inherited mitochondrial diseases. It was discovered in 2007 that DCA promotes human cancer cell death by a novel mechanism. Soon after this discovery, physicians began using DCA off-label for cancer treatment in a palliative setting. A case report is presented of a 71-year-old male with poorly differentiated carcinoma of unknown primary metastatic to the right leg and liver who achieved excellent palliation of leg pain by using oral DCA after failing conventional therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486148      PMCID: PMC3146743          DOI: 10.1089/jpm.2010.0472

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  6 in total

1.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Metabolic modulation of glioblastoma with dichloroacetate.

Authors:  E D Michelakis; G Sutendra; P Dromparis; L Webster; A Haromy; E Niven; C Maguire; T-L Gammer; J R Mackey; D Fulton; B Abdulkarim; M S McMurtry; K C Petruk
Journal:  Sci Transl Med       Date:  2010-05-12       Impact factor: 17.956

3.  Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

Authors:  D Ziegler; M Hanefeld; K J Ruhnau; H Hasche; M Lobisch; K Schütte; G Kerum; R Malessa
Journal:  Diabetes Care       Date:  1999-08       Impact factor: 19.112

4.  Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.

Authors:  Claudio Pisano; Graziella Pratesi; Diletta Laccabue; Franco Zunino; Pietro Lo Giudice; Augusta Bellucci; Licia Pacifici; Barbara Camerini; Loredana Vesci; Massimo Castorina; Sandra Cicuzza; Giovanni Tredici; Paola Marmiroli; Gabriella Nicolini; Stefania Galbiati; Menotti Calvani; Paolo Carminati; Guido Cavaletti
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

5.  Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.

Authors:  Roya Babaei-Jadidi; Nikolaos Karachalias; Naila Ahmed; Sinan Battah; Paul J Thornalley
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

6.  Clinical pharmacology and toxicology of dichloroacetate.

Authors:  P W Stacpoole; G N Henderson; Z Yan; M O James
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031

  6 in total
  3 in total

Review 1.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

2.  Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin.

Authors:  Tatsuaki Ishiguro; Ryumei H Ishiguro; Miyu Ishiguro; Atsushi Toki; Hiroshi Terunuma
Journal:  Cureus       Date:  2022-02-03

3.  Biophysical insights into cancer transformation and treatment.

Authors:  Jiří Pokorný; Alberto Foletti; Jitka Kobilková; Anna Jandová; Jan Vrba; Jan Vrba; Martina Nedbalová; Aleš Čoček; Andrea Danani; Jack A Tuszyński
Journal:  ScientificWorldJournal       Date:  2013-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.